BioSpace News Archive

Urovant Sciences, Inc., and Holly Robinson Peete Collaborate to Bring Awareness to Overactive Bladder (OAB) Symptoms and Management Options as Part of the Time To Go™ Campaign.

Tallac Therapeutics, Inc. today announced the appointment of Kevin N. Heller, M.D., as chief medical officer.

Sun Pharmaceutical Industries Limited and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) (“Concert”) today announced that they have executed a definitive agreement under which Sun Pharma will acquire all outstanding shares of Concert through a tender offer for an upfront payment of $8.00 per share of common stock in cash, or $576 million in equity value.

LinKinVax and Gustave Roussy announced a collaboration to conduct a first-in-human Phase I/IIa clinical trial with CD40HVac, a new therapeutic vaccine candidate against head and neck cancer associated with human papillomavirus (HPV).

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced the publication of the full results from the Company’s ELPIS I trial of Lomecel-BTM for hypoplastic left heart syndrome (HLHS) in the European Heart Journal Open.

Dyadic International, Inc. announced that it received approximately $1.27 million in connection with the sale of its equity interest in Alphazyme LLC.

BioCorRx Inc. today announced an update from the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals, Inc.

Viracta Therapeutics, Inc. today announced that the European Commission (EC) has granted an orphan drug designation (ODD) to Viracta’s all-oral combination product candidate, Nana-val (nanatinostat and valganciclovir), for the treatment of diffuse large B-cell lymphoma (DLBCL).

Nova Graphene Ballistics, Inc. (OTC PINK: BIEI), (“pending the name change from “Premier Biomedical Inc.”), announces the following steps, in pursuit of its first initiative 3D-printed Graphene Ballistic Plate Production, including the prototype, with regard to novel graphene production.

TC Biopharm (Holdings) PLC (“TC Biopharm” or the “Company”) (NASDAQ: TCBP) (NASDAQ: TCBPW), has received written notification from the listing qualifications staff of the Nasdaq Stock Market, LLC (“Nasdaq”) indicating that the Company has not regained compliance with the minimum Market Value of Listed Securities (“MVLS”).